Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ)
Taizhou, CN
Zhejiang Hisoar Pharmaceutical Co., Ltd. is a pharmaceutical enterprise that specializes in the manufacturing and global distribution of fine chemicals and specialized active pharmaceutical ingredients (APIs). Its diverse product portfolio encompasses materials used in the production of antibiotics, antiviral medications, cardiovascular drugs, and glucose-reducing agents, among others. Beyond these core APIs, the company also supplies pharmaceutical intermediates and provides customized processing services. Key products include clindamycin, the 4-AA Iso-carbapenem series, thiamphenicol, florfenicol, and voglibose. A significant portion of its output is destined for international markets through exports. Established in 1966, the company maintains its operational headquarters in Taizhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.03% | -1.43% | -16.11% | -31.85% | -11.54% | -11.54% | -12.80% | -40.77% | -36.91% | -35.81% | +86.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-4.0% Q1'26: +0.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+71.4% ★ Q1'26: +69.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-11.4% Q1'26: -14.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-0.6% Q1'26: +3.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-0.2% Q1'26: +1.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-3.5% ★ Q1'26: +69.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.60× Q1'26: 3.46× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.46B
est: 3.02B (-18.4%)
|
2.43B
est: 2.78B (-12.3%)
|
2.31B
est: 3.09B (-25.4%)
|
2.72B
est: 3.39B (-19.8%)
|
2.94B
est: 3.94B (-25.4%)
|
2.47B
est: 4.80B (-48.5%)
|
2.48B
est: 5.54B (-55.1%)
|
2.70B
est: 2.76B (-2.1%)
|
2.17B
est: 2.94B (-26.1%)
|
1.94B
est: 3.76B (-48.4%)
|
1.86B
est: 4.59B (-59.4%)
|
| EBITDA |
780.50M
est: 451.03M (+73.0%)
|
666.16M
est: 414.32M (+60.8%)
|
681.90M
est: 461.78M (+47.7%)
|
855.71M
est: 505.81M (+69.2%)
|
1.07B
est: 588.19M (+82.6%)
|
678.62M
est: 716.55M (-5.3%)
|
406.32M
est: 826.39M (-50.8%)
|
429.78M
est: 412.08M (+4.3%)
|
92.70M
est: 438.64M (-78.9%)
|
206.48M
est: 485.61M (-57.5%)
|
324.91M
est: 593.02M (-45.2%)
|
| EBIT |
599.55M
est: 38.21M (+1,469.1%)
|
468.30M
est: 35.10M (+1,234.2%)
|
500.57M
est: 39.12M (+1,179.5%)
|
663.34M
est: 42.85M (+1,448.0%)
|
870.76M
est: 49.83M (+1,647.4%)
|
422.05M
est: 60.70M (+595.3%)
|
117.18M
est: 70.01M (+67.4%)
|
98.14M
est: 34.91M (+181.1%)
|
-267.47M
est: 37.16M (-819.8%)
|
-131.53M
est: -85.37M (-54.1%)
|
-11.28M
est: -104.26M (+89.2%)
|
| Net Income |
516.59M
est: 935.76M (-44.8%)
|
225.02M
est: 314.54M (-28.5%)
|
342.22M
est: 401.04M (-14.7%)
|
605.00M
est: 487.54M (+24.1%)
|
770.78M
est: 1.09B (-29.0%)
|
319.72M
est: 1.34B (-76.1%)
|
95.23M
est: 1.60B (-94.1%)
|
88.01M
est: 251.63M (-65.0%)
|
-420.06M
est: 125.82M (-433.9%)
|
-330.27M
est: 242.87M (-236.0%)
|
-91.08M
est: 349.12M (-126.1%)
|
| SGA |
458.68M
est: 540.28M (-15.1%)
|
495.26M
est: 496.30M (-0.2%)
|
325.97M
est: 553.15M (-41.1%)
|
367.27M
est: 605.89M (-39.4%)
|
391.73M
est: 704.58M (-44.4%)
|
462.86M
est: 858.33M (-46.1%)
|
563.71M
est: 989.91M (-43.1%)
|
407.92M
est: 493.62M (-17.4%)
|
345.07M
est: 525.44M (-34.3%)
|
329.60M
est: 667.03M (-50.6%)
|
336.96M
est: 814.57M (-58.6%)
|
| EPS |
0.36
est: 0.60 (-39.5%)
|
0.15
est: 0.20 (-25.0%)
|
0.22
est: 0.26 (-13.7%)
|
0.38
est: 0.31 (+22.6%)
|
0.48
est: 0.69 (-30.4%)
|
0.20
est: 0.85 (-76.5%)
|
0.06
est: 1.02 (-94.2%)
|
0.05
est: 0.16 (-66.0%)
|
-0.26
est: 0.08 (-425.0%)
|
-0.21
est: 0.16 (-231.3%)
|
-0.06
est: 0.23 (-126.1%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 60.0K | 0.65% |
| 2 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.01% | 30.3K | 0.49% |
| 3 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 110.3K | 0.19% |
| 4 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 244.0K | 0.07% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 125.4K | 0.39% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 24.5K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 10.9K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.21M | 0.06% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 59.6K | 0.29% |
| 10 | Invesco FTSE All-World UCITS ETF FTWG.L | 0.00% | 27.5K | 0.15% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bing Yao | Vice President, Chief Financial Officer, Board Secretary & Director | — | male |
| Guangshun Chen | VP & Non Independent Director | — | — |
| Guorui Xu | GM & Director | — | male |
| Haiyan Zhou | Accounting Supervisor | — | — |
| Qing Hua Pan | Vice President | — | — |
| Wen Hua Mao | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002099.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
